Shandong Xinhua Pharmaceutical Company Limited Class H (HK:0719) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Shandong Xinhua Pharmaceutical Company Limited has announced the successful approval of a supplementary drug application for its pentoxifylline injections by the National Medical Products Administration. The approval signifies the company’s right to change the marketing license holder for the product. Additionally, the company disclosed a technology transfer contract with Suzhou Langke Biotechnology Co., Ltd., transferring the rights and interests related to the marketing and production technology of the drug.
For further insights into HK:0719 stock, check out TipRanks’ Stock Analysis page.